Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, August 24, 2023
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Monday, July 31, 2023
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Thursday, June 29, 2023
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global
Monday, June 12, 2023
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Tuesday, May 30, 2023
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
Monday, December 19, 2022
Gelonghui Reports CMS' Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets
Friday, November 18, 2022
China Medical System (867.HK) S&P Global CSA Score Achieved Significant Improvement, Leading the Industry Globally
Tuesday, September 6, 2022
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Monday, April 26, 2021
Starting its Industrial Investment in Biotech Companies, China Medical System (0867.HK) has Accelerated its Flywheel of Innovation
Monday, April 5, 2021
China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: